Compare · NVO vs PHIO
NVO vs PHIO
Side-by-side comparison of Novo Nordisk A/S (NVO) and Phio Pharmaceuticals Corp. (PHIO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and PHIO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $180.22B, about 20881.6x PHIO ($8.6M).
- PHIO has been more active in the news (11 items in the past 4 weeks vs 9 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 1 for PHIO).
- Company
- Novo Nordisk A/S
- Phio Pharmaceuticals Corp.
- Price
- -
- -
- Market cap
- $180.22B
- $8.6M
- 1M return
- +5.96%
- -
- 1Y return
- -14.37%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 9
- 11
- Recent ratings
- 25
- 1
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp., a biotechnology company, develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on silencing tumor-induced suppression of the immune system. The company develops PH-762, which targets the checkpoint protein PD-1 that prevent T cells from attacking various cells for used in adoptive cell transfer (ACT); PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for used in ACT; and PH-790 which targets PD-L1 protein that prevent cancer cells from inactivating T cells and attack the cancer. It has collaboration with AgonOx, Inc. on clinical development of novel immunotherapy drugs targeting key regulators of the immune response to cancer. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
Latest NVO
- Novo launches the new Novocare®: Free support program connects people with Wegovy® in addition to home delivery, everyday support, wellness partners and rewards
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routine
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest PHIO
- Amendment: SEC Form SCHEDULE 13G/A filed by Phio Pharmaceuticals Corp.
- Director Deming David H bought $9,823 worth of shares (12,000 units at $0.82), increasing direct ownership by 24% to 61,800 units (SEC Form 4)
- Director Deming David H bought $10,066 worth of shares (12,000 units at $0.84), increasing direct ownership by 32% to 49,800 units (SEC Form 4)
- Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
- Director Plott Ronald Todd bought $15,189 worth of shares (18,300 units at $0.83), increasing direct ownership by 44% to 60,300 units (SEC Form 4)
- Chairman, Pres. & CEO Bitterman Robert J bought $20,500 worth of shares (25,000 units at $0.82), increasing direct ownership by 3% to 789,871 units (SEC Form 4)
- Phio Pharmaceuticals Announces e-Presentation at American Society for Dermatologic Surgery (ASDS) Annual Meeting
- Phio Pharmaceuticals Announces Invitation for Oral Presentation at 41st Annual SITC Meeting (Society for Immunotherapy of Cancer)
- SEC Form 10-Q filed by Phio Pharmaceuticals Corp.
- Phio Pharmaceuticals Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits